AI assistant
LTR PHARMA LIMITED — Capital/Financing Update 2023
Dec 6, 2023
65273_rns_2023-12-06_64427c2b-b88c-4d6b-a9fe-294f195ae2a3.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
6 December 2023
==> picture [595 x 69] intentionally omitted <==
LTR Pharma Limited (ASX: LTP)
Pre-Quotation Disclosure
The following information is provided to ASX Limited ( ASX ) for release to the market in connection with the official quotation of shares ( Shares ) in LTR Pharma Limited (the Company or LTP ) (ASX: LTP).
Capitalised and abbreviated terms (not otherwise defined) in this document have the meaning given to them in the Replacement Prospectus lodged with the Australian Securities and Investments Commission on 9 November 2023 ( Replacement Prospectus ).
Completion of Offers
LTP confirms that the Offer closed on Friday, 24 November 2023 and allotment of 35,000,000 fully paid ordinary shares occurred on Tuesday, 5 December 2023 at an issue price of $0.20 per share.
LTP also confirms the issue of 250,000 ordinary fully paid shares to a nominee of Grannus Securities Pty Ltd occurred on Tuesday, 5 December 2023 and issue of 2,792,344 options exercisable at $0.26 each expiring three years from listing to nominees of Alpine Capital Pty Ltd occurred on Tuesday, 5 December 2023.
Despatch Date
The despatch date of CHESS allotment notices and issuer sponsored holding statements was Tuesday, 5 December 2023.
Statement of commitments
The Company confirms no change to the financial position as outlined in the Replacement Prospectus or to the expenditure program or statement of commitments as outlined in the Replacement Prospectus based on the actual amount of funds raised under the Replacement Prospectus.
Capital Structure
The capital structure of LTR following the completion of the Offer is as follows:
| Security | Number |
|---|---|
| Fully paid ordinary shares | 139,420,252 |
| Unlisted options | 4,792,344 |
Restricted Securities
The following table shows the number of restricted securities on issue in LTP and the applicable restriction periods.
| Security | Number | Restriction Period |
|---|---|---|
| Fully paid ordinary shares | 69,014,714 | 24 months from the date ofquotation |
| Options | 4,792,344 | 24 months from the date ofquotation |
==> picture [143 x 37] intentionally omitted <==
Authorised for release by Lee Rodne
Executive Chairman LTR Pharma Limited
For more information, please contact: LTR Pharma Limited
Belinda Cleminson, Company Secretary Email: [email protected]